<?xml version="1.0" encoding="UTF-8"?>
<ref id="B82-pharmaceuticals-12-00147">
 <label>82.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Haasbach</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Muller</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ehrhardt</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Schreiber</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Pleschka</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ludwig</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Planz</surname>
    <given-names>O.</given-names>
   </name>
  </person-group>
  <article-title>The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo</article-title>
  <source>Antivir. Res.</source>
  <year>2017</year>
  <volume>142</volume>
  <fpage>178</fpage>
  <lpage>184</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.024</pub-id>
  <?supplied-pmid 28377100?>
  <pub-id pub-id-type="pmid">28377100</pub-id>
 </element-citation>
</ref>
